What's being teased in the Breakthrough Wealth pitch from Dylan Jovine?
57 Comments Read MoreArticles
“#1 Micro-Cap Stock for February” teased — what’s up with this “1,000% gains starting February 22” pitch from Behind the Markets?
Cancer Treatment 2018: Looking Towards the Future
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
23 Comments Read MoreThe Miracle Cures Keep Coming
Doc Gumshoe looks at the "Did the Nazis Bury a True Cure for Cancer" ad from Brad Lemley
72 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
$POAI Predictive Oncology https://predictive-oncology.com/...
I got the privilege of watching ovarian cancer take the life of my older sister. She didn't smoke, watched what she ate,...
In 1975 Dr Richardson treated my mother, who had stage 4 ovarian cancer. The Laetrile made her vomit blood and rapid...
Be clear on this: NK cells are part of the INNATE immune system. But unless they work 100 percent and fully, tumors rela...
$Ovarian Cancer. Wow, early detections would be a godsend for all cancers, especially Ovarian cancer (OC). Terrible di...
$VBLTVBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cance...
$FATE long - Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Can...
I have a friend who rejected chemo/traditional treatment and went on Dr. Gonzalez's regimen some 20 years ago for her ov...
NP $ VBLT 07:01 VBLT Vascular Biogenics announces that the EMA has designated ofranergene obadenovec (VB-11...
$FATE long - Fate Therapeutics Reports Second Quarter 2017 Financial Results http://ir.fatetherapeutics.com/releasede...
$VBLT ow positionVBLT had its quarterly conference call today. Here are some highlights.The only thing I found ...
Good Dr. Interesting that you cite IPIX's (formerly CTIX) Kevetrin, which the FDA gave Orphan Drug designation to IPI...
My mom was a almost a 20.year ovarian cancer survivor..She was the bad ass in family. Always with grace. She outlive my ...
Hi Ron: Thanks for posting this. I had a look at Oncolix, whose lead agent is a single amino acid substituted protein th...
About $AEPP sp, Oncolix, and $ARTH fp Many thanks, Doc, for your new column….since reading it last evening ...
I need to take my daughter to the dentist, but wanted to throw this out there--yesterday (or this morning?) $VBLT releas...
$VBLT np – The data looks good. Dr. KSS when you get time, would love to hear your take on it. For both rGBM and Ovari...
$CLVS $TSRO #PARPHi Doc, I beg to differ - just slightly - with regard to your statement that "The agent (Clovis' ru...
$CLVS became the hottest takeout target in oncology this morning by announcing phase 3 data for PARPi rucaparib. The age...
$BIOC I think it's completely justified to be disappointed at the slow uptake since last years big jump. So far, it ap...
$TSRO - former long. *DJ TESARO Announces Availability of Zejula (Niraparib) for Patients With Recurrent Ovarian Cancer ...
RVW: be careful. First $TLOG may be planning to reverse merge....I'm not sure. Second, I have concerns this is not exact...
$CTIX SMALL LONGBEVERLY, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (the Compan...
TESARO (TSRO) Announces FDA Approval of its PARP Inhibitor, ZEJULA, for Treatment of Women With Recurrent Ovarian Cancer...
$TSRO TESARO Announces U.S. FDA Approval Of ZEJULA(TM) (Niraparib) For Women With Recurrent Ovarian CancerTESARO A...
$TSRO $CLVS $AZNSunTrust analyst just issued a research report on the competitive scene of PARP inhibitors:"TESA...
$TSRO longIt appears, as so often in bio, that this company's SP is reacting to news about a competitor.Astra-Ze...
I've done a little research on my own and the company doing the most research and development on gold protocal cancer tr...
Thanks for posting. I predict failure for this trial. You'd have to know the pathways and the molecular genetics, but pl...
$AZN $JNJ $NVS $PFE $NVO $RHHBY $GSK $TEVA $BIIB $LLY $TSRO $NBIX $KITE $PBYI*The top 15 would-be blockbusters in t...
$SNDX Syndax anticipates making a go/no go decision to progress into the second stage for each arm of ENCORE 601 in the...
$VBLT:VBL Therapeutics Provides Year End 2016 Corporate UpdateJanuary 9, 2017 TEL AVIV, Israel, Jan. 09, 2017 (...
STM: Please don't rush out to sell your $CLVS yet...the company did win an early approval on December 18, 2016 for its P...
re: Holdings.Thanks for both the initial suggestions and the offer to provide more granular feedback. I'll be the f...
$CLVS np but order in during halt! FDA approves ovarian cancer treatment RubracaLooking to scalp this today only....
$TSRO yes. I admit Tesaro kind of caught me napping. The problem is PARP inhibitors, which Tesaro has. There have been S...
As a $TSRO shareholder, I can share some of my experience.On June 30th Tesaro did a similar secondary (pricing and total...
J&J talc suit news; Short URL| Email Article| Comment| Contact| Print| A A After a $67.5 million jury verdic...
Unfortunately most mistakes are covered up and unreported. I had an older sister that didn't smoke or drink, ate the rig...
Very dazzling performance especially in ovarian cancer, with nearly half of all patients responding in some fashion. Ver...
$GILD $TSRO:I'd like to offer an alternative view: when and if Gilead makes a major move in acquisition, its growth...
Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research P...
This is in response to linling, who wrote last night asking about PARP inhibitors and the companies advancing them, such...
$BIOC no position. A company listed in London, ANGLE plc (AGL) and on OTC-QX (ANPCY), claims its ParsortixTM microfluidi...
Very nice and useful article Doc, thanks so much. As far as what a SPA means here is a link that explains thoroughly wha...
It is with profound interest to learn about this new Magic $1 Pill, so much so, I decided to subscribe to become a membe...
Recent advances in treating Ovarian Cancer.http://blog.aacr.org/recent-advances-treating-ovarian-cancer/Cheers,G...
I joined a trading app called Robinhood.com. I put $2000 in there. Had to wait 3 days for it to become active. Today I b...
I must admit I am disappointed at the relative lack of compellingness of the literature I have found on the talc/ovary c...
Epidemiology of talc and ovarian cancer http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820665/ http://www.ncbi.nlm.nih.g...
Doc, please let us know about the studies that do link talc with ovarian cancer, as what I am seeing does not point that...
Sharon: I say this just trying to have your back covered because I care about what happens to your investments: I agree ...
Seems safest bet is don't dust the rug. My mother died of ovarian cancer and i remember her being in clouds of talcum c...
JNJ: The International Agency for Research on Cancer (IARC) is part of the World Health Organization (WHO). Its major go...
Johnson and Johnson: Second woman awarded $86mil as baby powder can cause ovarian cancer. Anyone who is still long sho...
My mom had ovarian cancer in the early 90's. They did a hysterectomy.. then radiation.. She made it 18 years after..(whi...
interesting Stem Cell studies released today in Prostate and Ovarian Cancer. http://journals.lww.com/oncology-times/blo...
I am a medical practitioner. I look at this drug from a different perspective than I have been reading out there in 'te...
$CTIX Cellceutix meets fda phase-2 clinical trial kevetrin ovarian cancer http://seekingalpha.com/pr/16152296-cellceut...
For those still in $CTIX,: Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer...
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian CancerBEVERLY, MA--(Marketw...
Ovarian cancer drug shows promise with prostate cancer.http://www.ptcommunity.com/news/2015-10-29-000000/ovarian-can...
$CTIX: Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines ...
This New York Times article is important reading, particularly if you know someone with ovarian cancer.A treatment w...
A fascinating report out of MD Anderson this morning: among women with ovarian cancer who take beta-blockers for any ind...
Peering in at mid-day to answer Glenn's question about Oxigene, a $36M South San Francisco company that has stayed liste...
Doc Kss,when you get a chance could I get your thoughts on this company Oxigene(OXGN) and their drug ZYBRESTAT working w...
This company looks interesting Vermillion (VRML) with their OVA1 diagnostic blood test for pre-surgical assessment of ov...
Obviously if you're in $CTIX here, hold. But the casus diabli is this. Kevetrin is YEARS away from being proven to have ...
$CTIX Kevetrin granted Orphan Drug Designation for Ovarian Cancer yesterday. Here is the link: http://www.accessdata....
Yes, but for ovarian cancer, not breast...orphan drug designation made 7-14-15. Can't easily post a link right now but ...
Hi Sharon: Yes, while cancers do have elaborate immune-deterrent mechanisms, as long as they have an exposed surface mem...
Good article. (The Scientist becomes the Survivor and Advocate) fighting ovarian cancer. http://blog.aacr.org/laura-sha...
I've been flat on my back for the last three days with the Cold from Hell. so if I reiterate other posting I apologize i...
Hi Dr. KSSI mentioned 2 days ago about PBMD and that it was up 200% from .50 cents. Now today it is at $5.65. th...
Wow! Thanks for the input, Pat -- I bought a few shares of PBMD to make it correct downward. Positive phase II ovarian...
PBMD / just noticed the huge jump on this stock today, up over 200%.I am not a bio mind does anyone know anythin...
$KPTI. from leerink asco abstracts.• KPTI (OP): Ph II data for selinexor suggests single agent activity in solid...
Doc KSS, this company Novogen (NVGN) appear to have some very nice pre-clinical work in oncology and were once merged wi...
$CTIX-e-mail Best2ALL!-Benjamin My Fellow Cellceutix Shareholders, We are pleased to inform you that Cellceutix Chie...
One promising area is turning on the body's own defense against cancer -- the p53 "guardian angel" gene. CTIX announced ...
Diana, about $CTIX and your excellent comments above:(1) Personally I find Alexander's reassurances about the non-to...
Dr. thank you for the great continuing education about how to evaluate trial news and hypes! I listened again to the 201...
I am putting $CTIX on notice: THIS kind of press release has no place, and if this sort of thing continues I am exiting....
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Ant...
Northwest Biotherapeutic (NWBO) might deserve a mention in this list. NW Bio is Developing dendritic cell-based vaccines...
Scorpio, here is a link that works now: http://edge.media-server.com/m/p/ya62u49c Some new details fleshed out a little...
Certain traders who need to lighten up on the benzedrine. People read a press release and seem to have flipped because t...
It's a psychotic overreaction to news that is not bad. (1) the ovarian cancer is the least interesting of all TLOG stud...
TLOG-TetraLogic Provides Update on Ovarian Cancer Study 7:00a ET December 16, 2014 (GlobeNewswire) TetraLogic Pharmaceu...
Mary was asking about Clovis $CLVS. I can't say I have found anything negative to explain the recent down move. I think ...
$CLVS update on ovarian cancer trial Clovis Oncology, Inc. has added a news release to its Investor Relations web...
Interesting bullish article today on SA regarding $CLVS by an author who I follow. One of the key theses is that a ovar...
Will respond to more comments this evening, but one other thing in brief: Oxigene ($OXGN) recently presented data on its...
Thomas:(1) keep in mind that phase 1 will have no data til fall 2016...2 years away! Unless it proves highly toxic. ...
In my view, Atara is overpriced here. It appears to have only one agent in a phase 1 trial, one being studied in ovarian...
Glenn asked last night about $PBMD Prima BioMed, an early stage Australian company that has just purchased Paris immunol...
Dr.KSS: Any thoughts on a new IPO called Atara Biotechnology $ATRA? Impressive management. Partnership with MSKCC in dev...
I wonder if those same families who are insisting that everything possible be done, would do so if at least some of the ...